Physician profile
Victor Sein
NPI 1508882572
$1,973.35
in general payments reported to CMS, 2019-2025
25 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $69.58 · 2021: $109 · 2022: $82.30 · 2023: $133 · 2024: $516 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $446.97 | 2024-2025 | Lifevest |
| Abbott Laboratories | $266.23 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Assurity |
| Novartis Pharmaceuticals Corporation | $198.39 | 2020-2025 | |
| Edwards Lifesciences Corporation | $144.17 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $134.82 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $86.77 | 2023-2025 | Camzyos |
| Philips North America LLC | $65.17 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Bardy Diagnostics, INC. | $65.00 | 2019-2020 | |
| Boston Scientific Corporation | $58.30 | 2019-2025 | General - Vascular Intervention |
| Janssen Pharmaceuticals, INC | $58.23 | 2019-2021 | |
| Pfizer INC. | $49.47 | 2020-2025 | |
| Kestra Medical Technology Services, INC. | $48.71 | 2023 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $43.86 | 2025 | |
| Baxter Healthcare | $38.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $36.81 | 2024 | Wainua, Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $33.81 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals, LTD. | $32.83 | 2021-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $26.93 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.69 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $22.79 | 2024 | Nexletol |
| Ekos Corporation | $21.87 | 2019 | |
| Amgen INC. | $20.96 | 2025 | Repatha |
| Novo Nordisk INC | $18.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.50 | 2022 | |
| Preventice Services, LLC | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Sein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.